A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Summary

The purpose of this first-time-in-human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based monovalent vaccine (GSK4382276A) candidate against influenza in healthy younger adults (YA) and older adults (OA).

Timeline

Start

2022-08-09

Primary completion

2024-03-26

Completion

2024-03-26

Publications

• Leroux-Roels I, De Coster I, Borobia AM, Langley JM, Ochoa Mazarro D, Ruiz-Antoran B, Berre S, Germain S, Knauer C, Koch SD, Mann P, Mesia Vela D, Ovbude LJ, Pardo IA, Srivastava B, Moldt B, Nordgren M. Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation study. Hum Vaccin Immunother. 2026 Dec;22(1):2631804. doi: 10.1080/21645515.2026.2631804. Epub 2026 Feb 17.

Drugs

Indications